MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
GlycoMimetics, Inc. (NASDAQ: GLYC)*
Finance & Acquisitions: Glycomimetics
Parents
GlycoMimetics, Inc. (NASDAQ: GLYC)*
Children
*The company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.
2009: GlycoMimetics, Inc. Attracts $38 Million in Latest Venture Round (2009)
2011: GlycoMimetics Inc Inks Licensing Deal Worth Up to $340 Million with Pfizer Inc. (PFE) (2011)
2013: GlycoMimetics Files Registration Statement for IPO (2013)
2014: GlycoMimetics closes IPO, underwriters buy another 1 million shares (2014)
2014: GlycoMimetics collects $15M from Pfizer collaboration
2014: GlycoMimetics reaffirms IPO plans following delay (2013)
2014: GlycoMimetics sets IPO price range at $14 to $16 per share (2013)
2024: GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
2024: In support of the acquisition, a syndicate of investors led by Fairmount, Venrock Healthcare Capital Partners, BVF Partners, and a large investment management firm, with participation from Paradigm BioCapital, RTW Investments, Blackstone Multi-Asset Investing, Frazier Life Sciences, Commodore Capital, Perceptive Advisers, Deep Track Capital, Boxer Capital Management, Soleus, Logos Capital, Driehaus Capital Management, Braidwell LP, and Wellington Management, has committed $200 million to purchase GlycoMimetics common stock and GlycoMimetics pre-funded warrants to purchase its common stock
Glycomimetics Inc Stock Quote: GLYC Stock News, Quotes, Analysis
Glycomimetics_crunchbase
GlycoMimetics, Inc. (GLYC) Analyst Research
Jumps
*Key People: Glycomimetics
Organization & Developments: Glycomimetics